Fig. 6

The Menin-MLL1 inhibitor showed in vivo antitumor efficacy in AML-PDX (A-B) and ALL-PDX (C-D) models. A FCM analysis to demonstrate the kinetics of tumor burden (percentage of hCD45 + cells) in PB from AM7577 mice 31 days after inoculation (vehicle [days 0–23, QD × 24] or DS-1594a·HCl [25, 50, 100, and 200 mg/kg; days 0–34, QD × 35], n = 6 mice per group). B Kaplan‒Meier survival curves of AM7577 mice (vehicle [days 0–23, QD × 24] or DS-1594a·HCl [25, 50, 100, and 200 mg/kg; days 0–34, QD × 35], n = 6 mice per group). C FCM analysis to assess tumor burden (percentage of hCD45 + cells) 1 day after 28 days of treatment (day 38) in the BM of NCCHD007 mice (vehicle or 12.5, 25, and 50 mg/kg DS-1594a·succinate, n = 3 mice per group). D Kaplan‒Meier survival curves of NCCHD007 mice (vehicle or 12.5, 25, and 50 mg/kg DS-1594a·succinate; days 10–37, BID × 28, n = 6 mice per group). The significance of the survival curves was analyzed by the Kaplan‒Meier log-rank test, with survival time as the indicator of the life-prolonging effect of the test compound. BID, twice daily; mCD, mouse CD; NI, non-inoculated; PB, peripheral blood; QD, once daily